65984-53-4

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-bromophenyl)propan-1-amine is used as an intermediate in the synthesis of various pharmaceuticals for its ability to be incorporated into the molecular structures of drugs, enhancing their therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 3-(4-bromophenyl)propan-1-amine is used as a precursor in the development of agrochemicals, contributing to the creation of effective products for crop protection and enhancement of agricultural yields.
Used in Organic Synthesis:
3-(4-bromophenyl)propan-1-amine is utilized as a building block in organic synthesis, allowing for the construction of a wide range of organic compounds for various applications across different industries.

Upstream product

• 589-87-7 1,4-bromoiodobenzene 
• 1643-30-7 3-(4-bromophenyl)propionic acid 
• 4592-94-3 3-(4-bromophenyl)-3-oxopropanenitrile 
• 4654-39-1 4-bromophenethanol 
• 1746-28-7 1-bromo-4-(2-bromoethyl)benzene 
• 106-37-6 1.4-dibromobenzene 
• 1200-07-3 3-(4-bromophenyl)acrylic acid 
• 13565-09-8 4-bromocinnamoyl chloride 
• 27549-93-5 (E)-3-(4-bromophenyl)acrylonitrile 
• 65984-59-0 3-(4-bromophenyl)-3-hydroxypropanenitrile 
• 57775-08-3 3-(4-Bromo-phenyl)-propionitrile 
• 130973-06-7 p-bromocinnamamide 

Downstream Products

• 65984-66-9 N,N'-Bis-<3-(p-bromphenyl)propyl>-thioharnstoff 
• 150932-97-1 N-[3-(4-Bromo-phenyl)-propyl]-benzamide 
• 713541-85-6 N-[3-(4-bromophenyl)propyl]-N,N-dicyclobutylamine 

Relevant academic research and scientific papers

FERROPTOSIS INHIBITORS–DIARYLAMINE PARA-ACETAMIDES

Provided are compounds that inhibit ferroptosis activity, or modulate or inhibit a disease associated with ferroptosis dysregulation, such as neuropathy, ischemia reperfusion injury, acute kidney failure and cancer, including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

FORMAMIDE MONOMERS AND POLYMERS SYNTHESIZED THEREFROM

Formamide group-containing monomers and polymers made by polymerizing the monomers are provided. Also provided are methods of polymerizing the monomers and methods of synthesizing functionalized polymers by pre- and/or post-polymerization functionalizatio

Transition-metal-free Intramolecular C-H amination of sulfamate esters and: N -alkylsulfamides

The transition-metal-free intramolecular C-H amination of sulfamate esters using iodine oxidants, tert-butyl hypoiodite (t-BuOI) and N-iodosuccinimide (NIS) is reported. A method using NIS was also successfully applied to the oxidative cyclization of N-alkylsulfamides.

Diketopyrrolopyrrole derivative and application thereof

The invention provides a diketopyrrolopyrrole derivative and application thereof as well as relates to a diketopyrrolopyrrole derivative. The structural formula of the diketopyrrolopyrrole derivativeis as shown in a formula (I): the formula (I) is as shown in the description; in the formula (I), R1 is selected from a group as shown in a formula (I-a), a formula (I-b), a formula (I-c), a formula (I-d) or a formula (I-e) (the formulas are as shown in the description); and in the formula (I-a), the formula (I-b), the formula (I-c), the formula (I-d) and the formula (I-e), * shows connection position. The diketopyrrolopyrrole derivative has excellent photoelectric property and can be applied in the field of organic photoelectric functional devices.

N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase

The invention relates to compounds of formula (I) for treating for example sexual dysfunction, wherein R1 is optionally substituted C1-6alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, hydrogen, C1-6alkoxy, —NR2 R3 or —NR4SO2R5; X is the linkage —(CH2)n— or —(CH2)q—O— (wherein Y is attached to the oxygen); wherein one or more hydrogen atoms in linkage X may be replaced independently by C1-4alkoxy; hydroxy; hydroxy(C1-3alkyl); C3-7cycloalkyl; carbocyclyl; heterocyclyl; or by C1-4alkyl optionally substituted by one or more fluoro or phenyl groups; n is 3, 4, 5, 6 or 7; and q is 2, 3, 4, 5 or 6; and Y is phenyl or pyridyl, each of which may be substituted; or two R8 groups on adjacent carbon atoms together with the interconnecting carbon atoms may form a fused optionally substituted 5- or 6-membered carbocyclic or heterocyclyic ring.

Synthesis, structure and quantitative structure-activity relationships of σ receptor ligands, 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazines

A set of the title compounds having different substituents (R1, R2) on their phenyl groups was synthesized to find σ receptor binding affinity. Among the compounds, 2b (R1=R2=Cl) has the most potent σ1-binding activity, while 2a (R1=R2=H, SA4503) was most selective to σ1 over σ2 receptor. The crystal structures of 2a and 2b were shown, by X-ray crystallography, to be similar except for the one torsional angle of their propylene parts. Quantitative structure-activity relationship study suggested the affinity of the compounds to the σ1 receptor was dependent on the electronic feature, Swain-Lupton's R or S(π) that was derived by molecular orbital method, of R1 and R2.